An international multicenter, multi dose, randomized double-blind placebo-controlled clinical trial of a new pharmacological drug for tics. Children and adolescents aged 6-16 years with severe tics will be included. Participants will be randomized to the new drug or placebo. There will be close follow-up with weekly clinical visits or telephone calls during the trial and blood samples, ECG, and several diagnostic instruments will be administered ongoing.
After the trial, all participants will have opportunity to continue treatment with the new drug if it turns out to be effective.
September 2018 - september 2019
Nuvelution Pharma, Inc.